Madrigal Pharmaceuticals (MDGL) Stock
Biotech company developing liver and metabolic disease treatments. Here's the price, business snapshot, and what's worth knowing about Madrigal Pharmaceuticals in October 2026.
Madrigal Pharmaceuticals (MDGL) is a clinical-stage biopharmaceutical company focused on developing novel medicines for metabolic and liver diseases, notably non-alcoholic steatohepatitis (NASH). Its lead asset targets thyroid hormone receptor‑β with the aim of reducing liver fat and improving markers of liver health. As a specialist biotech with a market cap around $9.6 billion, Madrigal’s value is driven largely by clinical trial results, regulatory decisions and potential partnerships or commercialisation agreements. That creates both upside if trials succeed and significant binary downside risk if they do not. Investors should consider the company’s clinical timeline, regulatory pathway, balance sheet and broader NASH market dynamics. This summary is educational and not personalised financial advice; drug development is inherently risky, and past performance — or promising early data — does not guarantee future returns.
Madrigal Pharmaceuticals (MDGL) Stock Forecast
Analyst price target, next 12 months
$512.73
+2.7% vs today's $499.40
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Madrigal Pharmaceuticals have a consensus 12-month target of $512.73, above the current price of $499.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Madrigal Pharmaceuticals' stock with a target price of $512.73, indicating potential growth.
Financial Health
Madrigal Pharmaceuticals is performing well with strong revenue, high profitability, and solid cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalysts
Trial readouts and regulatory milestones can move the stock sharply; these events are worth watching but carry binary outcomes and significant risk.
Novel Mechanisms
Madrigal’s approach targets specific liver biology, which could address unmet needs; however, mechanism‑based promise does not ensure commercial success.
Market Position
The NASH market is large and competitive; successful approval could offer meaningful opportunity, though competition and reimbursement challenges remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
